Early Clinical Development of ARQ 197, a Selective, Non–ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
Alex A. Adjei(Roswell Park Comprehensive Cancer Center), Edward G. Garmey(Arqule (United States))
Cited by 72
Related Papers
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
|CA A Cancer Journal for Clinicians|2013|329